Hostname: page-component-6766d58669-nf276 Total loading time: 0 Render date: 2026-05-14T13:24:01.511Z Has data issue: false hasContentIssue false
  • English
  • Français

The effect of Zotepine on productive and negative symptoms in schizophrenic patients

Published online by Cambridge University Press:  28 April 2020

D.M. Dieterle ,
M. Ackenheil ,
H.P. Kapfhammer  and
F. Müller-Spahn
D.M. Dieterle
Affiliation:
Psychiatric Hospital of the University of Munich, Nussbaumstr. 7, 8000Munich 2, FRG
M. Ackenheil
Affiliation:
Psychiatric Hospital of the University of Munich, Nussbaumstr. 7, 8000Munich 2, FRG
H.P. Kapfhammer
Affiliation:
State Mental Hospital Regensburg, Universitätsstr., 8400Regensburg, FRG
F. Müller-Spahn
Affiliation:
Psychiatric Hospital of the University of Munich, Nussbaumstr. 7, 8000Munich 2, FRG
Get access

Résumé

Zotepine was studied in 15 schizophrenic patients over a period of 28 days with regard to its antipsychotic efficacy, effect on negative schizophrenic symptoms, tolerability and adverse effects. Nine patients received Zotepine in a high dosage of 230 mg/die±52 mg, 6 patients in a low dosage of 168 mg/die ± 18 mg. Two patients receiving the high dosage dropped out after 21 days because of worsening of symptomatology and suicide attempts. Zotepine had rapid antipsychotic effects with sedative properties during the initial days of treatment. Minimal adverse effects and extra-pyramidal motor disturbances as well as dose-dependent positive effects on negative schizophrenie symptoms were found.

Summary

Summary

La Zotepine a été étudiée chez 15 patients schizophrènes pendant une période de 28 jours pour évaluer son efficacité anti-psychotique, l‘e ffet sur les symptômes négatifs schizophréniques, sa tolérabilité et ses effets indésirables. Neuf patients ont reçu la Zotepine à un dosage élevé de 230 mg/jour ± 52 mg, 6 patients un dosage bas de 168 mg/jour ± 18 mg. Deux patients étaient exclus après 21 jours à cause d‘a ggravations de la symptomatologie et de tentatives de suicide. La Zotepine avait des effets antipsychotiques rapides avec des propriétés sédatives durant les premiers jours du traitement. Des effets secondaires négligeables, desperturbations motrices extrapyram idales ainsi que des effets positifs dose-dépendants sur les symptômes négatifs de la schizophrénie étaient constatés.

Keywords

ZotepineschizophreniaZotepineschizophrénie

Information

Type
Original article
Information
Psychiatry and Psychobiology , Volume 3 , Issue 2 , 1988 , pp. 125 - 130
Copyright
Copyright © European Psychiatric Association 1986

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Article purchase

Temporarily unavailable

References

Andreasen, N.C. (1981) Scale for the Assessment of Negative Symptoms (SANS). The University of Iowa, Iowa City, USAGoogle Scholar
Arbeitsgemeinschaft für Methodik und Dokumentation in der Psychiatrie (1972) In: AMP Manual zur Dokumentation Psychiatrischer Befunde.(Scharfetter, C., ed.), Springer Verlag, Berlin-Heidelberg-New York, 2nd ednGoogle Scholar
Baro, F. & Dom, R. (1976) The interaction between neuroleptic treatment and sociotherapeutie approach in chronic schizophrenics. Investigations with haloperidol, perfluridol and pimozide. Acta Psychiatr. Belg. 76, 735–758Google ScholarPubMed
Crow, T.J. (1980) Molecular pathology of schizophrenia, more than one disease process. Br. Med. J. 280, 66–68CrossRefGoogle ScholarPubMed
Crow, T.J. (1982) Positive and negative symptoms and the rate of dopamine in schizophrenia. In: Biological Aspects of Schizophrenia and Addiction. (Hemmings, G., ed.), Wiley & Sons LtdGoogle Scholar
De Buck, R.P. (1973) Relative safety and efficacy of high and low dose administration of fluphenazine-HCL to psychotic patients. In: Psychopharmacology, Sex Disorders, Drug Abuse.(Ban, T.A., ed.), North-Holland Publishing Co., Amsterdam, pp. 265–272Google Scholar
Deniker, P. & Ginester, D. (1973) Neuroleptiques. Encycl. Méd. Chir. Psychiatrie.vol. 20, 37860Google Scholar
Dieterle, D.M.Albus, M.T.Eben, E.Ackenheil, M. & Rockstroh, W. (1986) First results with the Andreasen Scale (Munich version). Assessment of productive and negative symptoms in chronic schizophrenic patients. Pharmacopsychiatria.3, 19, 96–100CrossRefGoogle Scholar
Gardos, G. & Cole, J.O. (1973) The Importance of dosage in antipsychotic drug administration - A review of dose-response studies. Psychopharmacology. 29, 221–230CrossRefGoogle ScholarPubMed
Gerlach, J.Behuke, K.Heltberg, J.Munkandersen, E. & Nielsen, H. (1985) Sulpiride and haloperidol in schizophrenia: a double-blind cross-over study of therapeutic effect, side effects and plasma concentrations. Br. J. Psychiatry. 147, 283–288CrossRefGoogle ScholarPubMed
Honda, F. & Mori, J. (1977) Effect of FR 1314 (Zote-pine), a new tricyclic neuroleptic, on serum prolactin levels in rats. Res. Lab., Fujisawa Pharmaceut., OsakaGoogle Scholar
Justin-Besançon, CThominel, N.Lavitte, U. & Margarit, J. (1967) Constitution chimique et propriétés biologiques du sulpiride. C.R. Acad. Sci. (Paris). 265, 1253–1254Google Scholar
Lai, A.Carino, M.A. & Horita, A. (1980) Antiserotonin properties of neuroleptic drug. In: Psychopharmacology and Biochemistry of Neurotransmitter Receptors. (Yamamura, Olsen & Usdin, eds.), North-Holland Publishing Co., Amsterdam, pp. 347–353Google Scholar
Lecrubier, Y.Puech, A.Simon, P. & Widlocher, D. (1980) Schizophrénie: hyper- ou hypofonctionnement du systéme dopaminergique? Une hypothèse bipolaire. Psychol. Med., 2431–2441Google Scholar
Lewine, R.J. (1985) Negative symptoms in schizophrenia: editor's introduction. Schizophr. Bull. 11(3), 361–363CrossRefGoogle Scholar
Mackay, A.V.P. (1980) Positive and negative schizophrenic symptoms and the rate of dopamine. Br. J. Psychiatry. 137, 379–386CrossRefGoogle Scholar
Maj, J.Sarnek, J.Klimek, V. & Rawlow, A. (1976) On the anticataleptic action of cyproheptadine. Pharmacol. Biochem. Behav. 5, 201–105CrossRefGoogle ScholarPubMed
Overall, J.E. & Gorham, D.R. (1976) 047 BPRS-brief psychiatric rating scale. In: Assessment Manual for Psychopharmacology.(Guy, W.,ed.), Rockville, Maryland, pp. 157–169Google Scholar
Puech, A.J.Simon, P. & Boissier, I.R. (1978) Benza-mides and classical neuroleptics: comparison of their actions using apomorphine induced effects. Eur. J. Pharmacol. 50, 291–300CrossRefGoogle ScholarPubMed
Puech, A.J. & Martin, P. (1987) Classification of neuroleptics - Zotepine. Pharmacopsychiatria. 20, 1&3CrossRefGoogle ScholarPubMed
Riviera, Calimlin L.Nastallah, H.Strauss, I. & Lasagna, L. (1976) Clinical response and plasma levels: effect of dose, dosage schedules, and drug interactions on plasma chlorpromazine levels. Am. J. Psychiatry. 133, 646–652Google Scholar
Shimomura, K.Saton, H.Hivai, O.Mori, J.Tomoi, T.Terai, T.Katsuki, S.Motoyama, Y. & Ono, T. (1982) The central anti-serotonin activity of Zotepine, a new neuroleptic, in rats. Jap. J. Pharmacol. 32, 405–412CrossRefGoogle ScholarPubMed
Sulpizio, A.Fowler, P.J. & Macko, E. (1978) Antagonism of fenfluramine induced hyperthermia: a measure of central serotonin inhibition. Life Sci. 22, 1439–1446CrossRefGoogle ScholarPubMed
Torii, H.Yoshimoto, H. & Hiraguchi, M. (1979) Treatment with Zotepine for schizophrenics. Pharmacol. 7, 125–152Google Scholar
Tsujimura, R. & Nomura, J. (1979) Clinical trial of Zotepine for schizophrenic patients. Pharmacol. Ther. 7, 100–124Google Scholar
Webster, D.D. (1968) Critical analysis of disability in Parkinson's disease. Med. Treat. (Tokyo). 5, 257–282Google ScholarPubMed
Submit a response

Comments

No Comments have been published for this article.